Brief: Syndax Pharmaceuticals Q4 Operating Expenses USD 131.276 Million
26/02/2026 21:01
Feb 26 (Reuters) - Syndax Pharmaceuticals Q4 operating income USD -62.548 million. Q4 net income USD -68.014 million vs. IBES estimate USD -50.1 million
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million